The role of bone marrow-derived stem cells in the repair of pulmonary epithelium

Lead Research Organisation: Imperial College London
Department Name: Dept of Medicine


Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.


10 25 50
Description Deelopment of a hybrid lung-assist device
Amount £118,089 (GBP)
Organisation Novalung 
Sector Private
Country Germany
Start 01/2007 
End 12/2008
Description Developing practical applications of stem cell therapy
Amount £670,000 (GBP)
Organisation Department for Business, Energy & Industrial Strategy 
Sector Public
Country United Kingdom
Start 01/2005 
End 12/2008
Description Dr K Bhakoo, MRC CSC 
Organisation Medical Research Council (MRC)
Department MRC Clinical Sciences Centre (CSC)
Country United Kingdom 
Sector Public 
PI Contribution NA
Collaborator Contribution FITC-conjugated iron oxide nonparticles for labelling and tracing of implanted stem cells
Impact NA
Description Dr M Takata, Academic Anaesthetics, Chelsea and Westminster Hospital 
Organisation Chelsea and Westminster Hospital NHS Foundation Trust
Department Academic Anaesthetics
Country United Kingdom 
Sector Academic/University 
PI Contribution NA
Collaborator Contribution Mice with LPS induced lung injury for implantation of differentiated stem cells
Impact NA
Description Professor J Wallwork and Dr R Mahadeva, Papworth Hospital 
Organisation Papworth Hospital NHS Foundation Trust
Country United Kingdom 
Sector Public 
PI Contribution NA
Collaborator Contribution Mice with elastase and smoke induced lung injury for implantation of differentiated stem cells
Impact NA
Description Professor J Whitsett, Cincinatti Children's Hospital 
Organisation Cincinnati Children's Hospital Medical Center
Country United States 
Sector Hospitals 
PI Contribution NA
Collaborator Contribution Surfactant protein C genomic DNA containing promoter elements sub-cloned into a promoter-less pEGFP vector, and practical guidance on stem cell transfection that allowed us to isolate and trace alveolar epithelial cells differentiated from stem cells
Impact NA
Title Preparation of type II pneumocytes from stem cells 
Description Stem cells are induced in culture to form cells which express surfactant protein C (SPC), thereby offering a convenient and abundant supply of alveolar tissue without requiring lung donation or the use of cadavers. Stem cells are cultured to give embryoid bodies, which are they maintained under conditions which cause them to differentiate into cells which express SPC. SAGM medium has been found to be particularly effective for causing differentiation of the embryoid bodies. 
IP Reference US2005244960 
Protection Patent granted
Year Protection Granted
Licensed Yes
Impact Formed part of the major IP for establishing NovaThera Ltd, collaboration has allowed application for funding not available to academic groups.
Company Name Novathera Ltd. 
Description NovaThera Ltd. was spun-out of Imperial College London in 2003. It specialises in pioneering applications of biomaterials and stem cell biology for regenerative medicine and tissue engineering to provide innovative therapeutic solutions. NovaThera has a relationship with Imperial College to continue commercialisation of the current and future technologies emanating from the Tissue Engineering and Regenerative Medicine Centre ("TERM"), a world-class research centre combining biology, biomaterials and bio-photonics expertise. 
Impact The DTI invested via Novathera in furthering regenerative medicine research. Novathera developed a novel rotating bio-processor system (NovaPod®) for stem cells with MediHealth Ltd a Hong Kong company - announced in 2007. Novathera developed TheraGlass®, a novel bioactive glass which interacts with the body's tissues to stimulate cell growth and has spawned technologies with potential uses from craniofacial reconstruction to drug delivery. In 2008 Novathera merged with MedCell Bioscience Ltd, a Newmarket-based regenerative medicine company with an interest in veterinary applications of stem cell technology. The combined company continued under the name MedCell Biosciences Ltd.